Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 15/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446562 | 0.88 | NSD2 (0.65) | NSD2POLB | |
| Hydrochloric Acid SCHEMBL4448775 | 0.87 | NSD2 (0.65) | NSD2 | |
| Hydrochloric Acid SCHEMBL6908166 | 0.85 | NSD2 (0.68) | NSD2GAA | |
| SCHEMBL4443030 | 0.83 | NSD2 (0.74) | NSD2 | |
| Hydrochloric Acid SCHEMBL4444986 | 0.82 | NSD2 (0.74) | NSD2 | |
| SCHEMBL4443339 | 0.81 | NSD2 (0.67) | NSD2ALDH1A1GAA | |
| SCHEMBL4448425 | 0.81 | TP53 (0.46) | ALDH1A1POLBMAPTHPGDALOX15 | |
| SCHEMBL4446873 | 0.81 | NSD2 (0.62) | NSD2 | |
| Hydrochloric Acid SCHEMBL4448338 | 0.80 | NSD2 (0.67) | NSD2ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL4448811 | 0.80 | NSD2 (0.63) | NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547716-B2 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-06-16 | — | — | US | claimed |
| US-7547716-B2 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1402890-B1 | SULFONAMIDE DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1402890-A1 | SULFONAMIDE DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | NSD2 122/4885ALDH1A1 980/4885POLB 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.